Of the 17 032 women in the study, 15 292 remained under observation on reaching the age of 45. At that age, each woman was allocated to one of three groups: (a) oral contraceptives never used (5881 women), (b) oral contraceptives used for a total of 8 years or more (3520 women) and (c) other durations of oral contraceptive use (5891 women). Only the women in the two groups first mentioned were followed up from then on in the detailed way described above. Accordingly, women in group (c) have been omitted from the present analysis from the age of 45 onwards.
A large number of case-control studies have shown that oral contraceptives protect against cancer of the endometrium (Cancer and Steroid Hormone Study, 1987a; World Health Organization Collaborative Study, 1988; Hankinson et al., 1992) and epithelial ovarian cancer (Cancer and Steroid Hormone Study, 1987b ; World Health Organization Collaborative Study, 1989; Vessey, 1989) . Data from cohort studies, however, are few. We report here the results obtained from the Oxford Family Planning Association (Oxford FPA) contraceptive study up to October 1993.
Materils and mthos
A detailed description of the methods used in the Oxford FPA study has been given elsewhere (Vessey et al., 1976) . In brief, 17032 women were recruited at 17 large family planning cinics in England and Scotland between 1968 and 1974 . At the time of recruitment, each woman had to be (a) aged 25-39, (b) The analysis is based on the computation of woman-years of observation in the various groups of interest with the calation of indirectly standardised rates by the method described by Vessey et al. (1976) . In the analysis of endometrial cancer, women in the study were deleted once they had undergone hysterectomy, while in the analysis of ovarian cancer women were deleted once they had experinced bilateral oophorectomy. There were 15 endometrial cancers and 42 epitheial ovarian cancers included in the analysis. It should be noted that, of the 42 ovarian cancers, five were judged to be of borderline malignancy while the pathologist was not absolutely certain that another three were primary tumours.
Res
We conducted the analyses described below separately for women aged up to 45 and for women aged 45 or more. The results in the two sets of analyses were closely similar, accordingly, we present only the overall figures here.
Of the 15 women with endometrial cancer, only one had ever used oral contraceptives, resulting in an age-adjusted relative risk for ever users vs never users of 0.1 (95% confidence interval 0.0-0.7). Clearly, no more detaied analysis was possible with such small numbers of cases.
Ovarian i) heterogeneity 12.0 (P = 0.007). Standardised for age and parity (see Table I ).
number of authors (see Hankinson et al., 1993) . We were unable to detect such an association in our data. Thus, the age-and parity-adjusted relative risk of ovarian cancer for erilised women in comparison with non-stefilised women was 1.5 (95% confidence interval 0.7-3.1).
The age-and parity-adjusted relative risk of ovarian cancer for ever users vs never users of oral contraceptives was 0.4 (95% confidence interval 0.2-0.8). There was also a clear negative relationship between duration of oral contraceptive use and the risk of ovarian cancer (Table 1 ). This effect was not apparent among women using oral contraceptives for up to 4 years, but was strong for longer durations of use. Table H ex s the association between interval since last use of oral contraceptives and ovarian cancer risk. The apparent protective effect was greatest in the recent user category (within the last 4 years) and was barely apparent in those who had last used oral contraceptives more than 8 years before.
We were unable to carry out any useful analysis according to oral contraceptive type in view of the paucity of the data.
As mentioned in the introduction, a substantial number of case-control studies have documented an apparent protective effect of oral contraceptive use against endometrial cancer. Of these, the two best known are the Cancer and Steroid Hormone Study (1987a) and the World Health Organization Collaborative Study (1988) . The first of these studies, conducted in the USA, included 433 cases and 3191 controls. It was found that women who had used combination oral contraceptives for at least 12 months had an ageadjusted risk of developing endometrial cancer of 0.6 (95% confidence interval 0.3-0.9) relative to women who had never used oral contraceptives. Furthermore, this protective effect was found to persist for at least 15 years after cessation of oral contraceptive use. The second (international) study, which included 130 cases and 835 controls, found that the relative risk for ever use vs never use of oral contraceptives was 0.55 (95% confidence interval 0.26-1.17). A number of other case-control studies, all suggesting a protective effect, have been summarised by Vessey (1989) .
The few data available from cohort studies have given similar results. In the Walnut Creek Contraceptive Drug Study (Ramcharan et al., 1981) , there were 18 cases of endometrial cancer in the ever user group and 40 in the never user group, giving a relative risk of 0.6 (95% confidence interval 0.3-0.9). The Royal College of General Practitioners Oral Contraception Study (Beral et al., 1988) found two cases of 'cancer of the uterus except cervix' in ever users of oral contraceptives and 16 in never users, resulting in a relative risk of 0.2 (95% confidence interval 0.0-0.7). Clearly, our findings match very closely with those of the Royal College; although both studies suggest a very marked protective effect of oral contraceptives against endometrial cancer, the confidence limits indicate consistency with other results.
The literature concerning a protective effect of oral contraceptives in relation to epithelial ovarian cancer is more extensive than that relating to endometrial cancer. Hankinson et al. (1992) have provided a recent overview of 20 studie. They reported that the summary relative risk associated with ever use of oral contraceptives was 0.64 (95% confidence interval 0.57-0.73). In addition, the risk of ovarian cancer decreased with increasing duration of oral contraceptive use so that there was a 50% decrease in risk after 5 years' use. This reduced risk appeared to persist at least 10 years after cessation of use. Thus, compared with never users, women who had stopped using oral contraceptives 10 or more years before had a summary relative risk of 0.60 (95% confidence interval 0.42-0.86).
As (Beral et al., 1988) . The corresponding relative risk was 0.6 (95% confidence interval 0.3-1.4). Our results are an important addition to the cohort study literature on ovarian cancer and provide further (and statistically significant) evidence of a protective effect of oral contraceptive use. There are only two features of our data which are slightly disturbing; first, no protective effect was apparent until oral contraceptives had been used for more than 4 years and, second, there was evidence of some reduction in the benefit with increasing interval since last use of oral contraceptives. These observations are, however, based on small numbers and clearly do not contradict the overview findings reported by Hankinson et al. (1992) .
While a beneficial effect of oral contraceptives with respect to endometrial cancer is important, the similar effect with respect to ovarian cancer is even more so since ovarian cancer is such a deadly disease. It is encouraging to note that in several countries a decline in the mortality from ovarian cancer in women under 55 years has been noted since the early 1970s (Mant and Vessey, 1994) . This may well reflect an effect of oral contraceptive use.
